![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR: DATA FROM THE GERMAN HEPATITIS C-REGISTRY
|
|
|
Reported by Jules Levin
EASL 2019 April 10-14 Vienna
Markus Cornberg1, Albrecht Stoehr2, Uwe Naumann3, Hartwig Klinker4, Thomas Lutz5, Willibold Schiffelholz6, NazifaQurishi7, Andreas Pangerl8,Kristina Lohmann8, Bettina Koenig8, Karl-Georg Simon9
1MedizinischeHochschule Hannover, KlinikfürGastroenterologie, Hepatologieund Endokrinologie, Hannover, Germany; 2. IFIStudienund ProjekteGmbH, Hamburg, Germany; 3. UBN-Praxis, Berlin, Germany; 4. University Hospital Würzburg, Würzburg, Germany; 5. Infektiologikum, Frankfurt, Germany; 6. GastroenterologischeSchwerpunktpraxis, Augsburg, Germany; 7. GemeinschaftspraxisGotenring, Cologne, Germany; 8. AbbVie Inc., North Chicago, Illinois, USA; 9. MVZDresEisenbach/Simon/ Schwarz/GbR, Leverkusen, Germany
![0412191](../images/041219/041219-8/0412191.gif)
![0412192](../images/041219/041219-8/0412192.gif)
![0412193](../images/041219/041219-8/0412193.gif)
![0412194](../images/041219/041219-8/0412194.gif)
![0412195](../images/041219/041219-8/0412195.gif)
![0412196](../images/041219/041219-8/0412196.gif)
![0412197](../images/041219/041219-8/0412197.gif)
![0412198](../images/041219/041219-8/0412198.gif)
![0412199](../images/041219/041219-8/0412199.gif)
![04121910](../images/041219/041219-8/04121910.gif)
![04121911](../images/041219/041219-8/04121911.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|